Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Aronson

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
American Journal of Hematology|August 1, 1987
Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2F R Aronson, R A Dempsey, M Allegretta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II studyD R Parkinson, J S Abrams, P H Wiernik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicityJ A Sosman, F R Aronson, M Sznol, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
American Journal of Hematology|August 1, 1987
Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2F R Aronson, R A Dempsey, M Allegretta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II studyD R Parkinson, J S Abrams, P H Wiernik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicityJ A Sosman, F R Aronson, M Sznol, et al.
Pageof 3